By Deron Hamel TORONTO – Anyone who has taken the anti-seizure medication Primidone to control their epilepsy in the past three years should speak to their pharmacist to determine if their prescription has been affected by a recent recall, says Epilepsy Ontario board member Rahim Ismail. On April 6 manufacturer AA Pharma Inc. voluntarily recalled…
By Deron Hamel Monika and Adam, a couple from Toronto, say they were “shocked” to learn in January that the new Ontario Health Insurance Plan (OHIP) drug program OHIP+ will not cover the cost of their four-year-old daughter Ava’s anti-seizure medication. OHIP+, which came into effect Jan. 1, is providing more than 4,400 drug products…
By Deron Hamel Research programs aimed at enhancing quality of life for people with epilepsy are the most important avenue of research to those living with seizure disorders, their families and people working at epilepsy support agencies, according to a recent EpLink survey. EpLink’s “research priorities” online survey had 139 respondents. The survey, which was…
By Deron Hamel The Ontario government is asking for input from people who have had experience living with uncontrolled focal onset seizures for an upcoming assessment of a new anti-seizure drug. An expert committee, established by the province to review medications, will assess this input along with clinical trial data and an economic evaluation of…
Sponsor Image 1
Sponsor Image 2
Sponsor Image 3
Sponsor Image 1
Sponsor Image 2
Sponsor Image 3
